A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status

Published:2020-06-30 Issue:7 Volume:47 Page:5263-5271
ISSN:0301-4851
Container-title:Molecular Biology Reports
language:en
Short-container-title:Mol Biol Rep

Author:

Vázquez-Blomquist Dania,Leenstra Sieger,van der Kaaij Mariëlle,Villarreal Adelaida,Bello-Rivero Iraldo

Funder

UICC International Cancer Technology Transfer Fellowship

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11033-020-05604-2.pdf

Reference43 articles.

1. Rybalkinaa E, Pavlovab G, Stavrovskayaa A (2015) Recent news in the glioblastoma research. Biochem (Mosc) Suppl Ser Membr Cell Biol 9:1–12

2. Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 4:54

3. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

4. Szopa W, Burley TA, Kramer-Marek G, Kaspera W (2017) Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives. BioMed Res Int. https://doi.org/10.1155/2017/8013575

5. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-B down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65:7573–7579

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing: A Potentially Emerging Discipline;Indian Journal of Pharmaceutical Education and Research;2022-05-16

2. Repurposing approved drugs for cancer therapy;British Medical Bulletin;2021-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3